1951–1964

Diffusion-Controlled Release in Solids

Contemporary themes

During the 1951-1964 period, diffusion emerges as the central design principle for controlled release across disciplines. Researchers formulate diffusion-dominated kinetics to explain sustained action of solid-dose systems and implantable carriers, while parallel work investigates diffusion processes in materials to optimize device performance. The cross-disciplinary emphasis on diffusion creates a unifying framework that ties pharmacology, materials science, and energy-release phenomena together, guiding the early development of solid matrices and polymer-based carriers with predictable, time-delayed release.

• Radiation-induced defect physics drives a unified program: probing defect centers, irradiation effects, and charge transport in solids through spectroscopy and energetic perturbations, unifying silicon defects, infrared absorptions, and energy-release phenomena.[2][6][12][15][17]
• Instrumentation and measurement focus on developing and characterizing radiation sensors: plastic scintillators, liquid scintillators, semiconductor detectors, glow discharge mass spectrometry, and diagnostic glow discharge measurements.[1][5][7][8][9][11]
• Diffusion as a design paradigm in semiconductors: intentional diffusion of donors/acceptors and copper diffusion to tailor electronic properties in silicon and GaAs, highlighting diffusion-controlled formation of p-type materials and transport behavior.[3][15][19]
• Cross-domain release phenomena: sustained/controlled release concepts in pharmacology and energy-release in materials, with mathematical treatment, diffusion-controlled release, and release-mechanism investigations across papers.[4][5][10][16][18]

Influential works

The era lays a durable foundation for diffusion-controlled release science. The diffusion-dominated release paradigm provides both theoretical and practical bases for designing long-acting therapies and enduring carrier systems. Innovations such as polymeric and solid-matrix carriers demonstrate the feasibility of predictable release, and the conceptual lineage from diffusion-driven models inspires later approaches to responsive and sustained-release technologies across related fields.

• Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices[1] introduced a diffusion-dominated release model from solid matrices, establishing the quantitative basis for controlled-release kinetics and guiding generations of sustained-delivery formulations.
• The use of silicone rubber as a carrier for prolonged drug therapy[4] demonstrated silicone rubber as a biocompatible polymer matrix for long-term, controlled drug release, pioneering implantable delivery devices and influencing later polymer-based approaches to sustained therapy.
• The Enzymology of Control by Feedback Inhibition[5] presents how feedback regulation governs enzymatic pathways, providing a conceptual blueprint for responsive drug-release systems that adjust to physiological cues and regulate bioavailability, shaping early ideas in controlled delivery design.

1965–1994

Biodegradable Polymer Delivery

Contemporary themes

Contemporary Themes: During 1965–1994, polymer-based carriers and bioadhesive platforms formed the core of sustained-release strategies, utilizing biodegradable matrices and mucosal adhesion to enable prolonged oral and injectable delivery. Release kinetics were guided by diffusion, swelling, and pH-responsive behavior, with modeling providing predictive tools for matrix selection and release profiles. Hormonal and biologic therapies favored long-acting injectables and PLGA-based microspheres, while bioadhesion-focused oral delivery studies sought to extend residence time and control release in the oral cavity.

• Polymer-based carriers and bioadhesive platforms unify sustained release strategies across molecules, with biocompatible matrices, protein-based beads, and mucosal adhesion enabling controlled oral/prolonged delivery[3][9][10][16][17].
• Modeling release mechanisms—diffusion, swelling, and pH‑sensitive behavior—provides predictive design tools guiding matrix selection and release kinetics[2][7][14][18].
• Hormonal and biologic delivery systems emphasize long-acting injectables and PLGA-based microspheres with continuous/intermittent regimens for progesterone/LHRH and other biologics[6][11][12][15].
• Bioadhesion-focused oral delivery studies investigate adhesion mechanisms, measurement methods, and platforms to extend residence time and control release in the oral cavity[3][4][16].

Influential works

Influential Works: A widely adopted power-law framework for describing polymeric release mechanisms emerged, enabling classification into Fickian, non-Fickian, and anomalous transport across swellable and non-swellable systems. Self-assembled block copolymer micelles established versatile nanocarriers capable of solubilizing hydrophobic drugs and tailoring release profiles. Biodegradable hydrogels and hydrogel swelling dynamics became foundational for implantable and injectable delivery, while liposome design demonstrated thermally triggered and localized release, foreshadowing future responsive therapies.

• Korsmeyer and Peppas introduced a simple power-law equation to describe solute release from polymeric devices, distinguishing Fickian, non-Fickian, and anomalous mechanisms for both swellable and non-swellable systems; the I and II papers became the universal framework for fitting release data across controlled-release formulations.[5][2]
• Block copolymer micelles as vehicles for drug delivery introduced self-assembled micellar carriers from block copolymers, enabling solubilization of hydrophobic drugs and tunable release profiles; this concept catalyzed a vast polymeric DDS research program and remains foundational for nanocarrier design.[3]
• Biodegradable Hydrogels for Drug Delivery surveys designs of degradable hydrogel networks, their synthesis, degradation behavior, and release characteristics, establishing biodegradability as a key to implantable and injectable DDS.[12]
• Hydrogels: swelling, drug loading, and release provides a comprehensive treatment of hydrogel swelling kinetics and loading/release mechanisms, shaping later innovations in responsive and controlled-release hydrogels.[9]
• Design of Liposomes for Enhanced Local Release of Drugs by Hyperthermia presents liposome engineering to achieve localized, thermally triggered release, a concept precursor to heat-sensitive and targeted liposomal therapies.[7]

1995–2001

Stimuli-Responsive Drug Delivery

Contemporary themes

The late 1990s to early 2000s marked a shift toward multifunctional carriers enabling targeted, sustained release. Self-assembled polymeric nanocarriers, notably block copolymer micelles and solid lipid nanoparticles, plus diffusion- and swelling-controlled hydrogel matrices and bioadhesive systems, defined the dominant experimental directions. Environment-responsive strategies—thermo- and pH-sensitive polymers and poloxamer-based delayed-release systems—emerged as core modalities for programmable therapy. Modeling efforts integrating diffusion, swelling, and dissolution mechanisms provided predictive frameworks for formulation design, while biocompatibility and safety considerations increasingly guided the development of long-acting and implantable delivery platforms across polymeric and inorganic carrier classes.

• Self-assembled polymeric nanocarriers, chiefly block copolymer micelles and solid lipid nanoparticles, enable selective encapsulation and sustained release, with long-circulating and tumor-targeting capabilities demonstrated across micelle-based systems and biodegradable carriers[1][3][4][5][13].
• Hydrogel networks, hydrophilic matrices, and bioadhesive delivery systems provide diffusion- and swelling-controlled release paradigms, spanning hydrogel-based delivery, HPMC matrices, and chitosan/bead systems for long-acting/peroral applications[6][7][12][15][17][20].
• Environment-responsive release strategies leverage temperature, pH, or external stimuli to modulate release kinetics, exemplified by thermo/pH-sensitive terpolymers and thermo-sensitive microcapsules, plus poloxamer-based delayed-release systems[10][11][16].
• Modeling-focused work integrates diffusion, swelling, and dissolution mechanisms into predictive frameworks, including hydrophilic-matrix scaling laws and matrix-release kinetics models that guide formulation design[6][14][18].
• Biocompatibility and safety considerations shape implantable and long-acting delivery approaches, addressing material-tissue interactions, degradation, and in vivo performance constraints across polymeric and microsphere-based systems[9][20].

Influential works

• Polymeric Systems for Controlled Drug Release (1999)[2] synthesizes a framework linking diffusion, matrix erosion and release kinetics, guiding polymer selection, device design, and evaluation methods; its integrated view redirected decades of polymer-based delivery research.
• Block copolymer micelles for drug delivery: design, characterization and biological significance (2001)[4] details self-assembly, core–shell structures, loading strategies and stability, establishing micellar carriers as a dominant platform and inspiring vast in vivo translation.
• Environment-sensitive hydrogels for drug delivery (2001)[3] introduces stimuli-responsive gels that modulate swelling and release in response to pH, temperature or ions, enabling on-demand release and programmable therapeutics that shaped smart delivery.
• A New Property of MCM-41: Drug Delivery System (2000)[6] shows mesoporous silica MCM-41 as a drug carrier with high surface area and tunable pores, enabling high loading and controlled release and spurring growth of inorganic–organic hybrid nanocarriers.

2002–2009

Stimuli-Responsive Nanocarrier Engineering

Contemporary themes

During 2002–2009, the dominant pattern was diversification of carrier materials for controlled release, spanning polymer microspheres, PLGA–PEG nanoparticles, silica, and lipid matrices to support parenteral, oral, and mucosal delivery. A second convergence centered on stimuli-responsive and trigger-based release mechanisms, including pH-triggered silica, magnetic caps, smart hydrogels, redox-sensitive carriers, and light-activated systems, enabling on-demand delivery. Complementing these advances, mechanistic release kinetics modeling, surface engineering, mucoadhesion, and targeting strategies sharpened design predictability and facilitated broader adoption of drug-delivery technology in pharmaceutical development.

• Carrier design diversified across materials—polymer microspheres, PLGA–PEG nanoparticles, silica and lipid matrices—enabling versatile controlled-release platforms across parenteral, oral, and mucosal routes[1][4][8][9][10][13].
• Stimuli-responsive and trigger-based release mechanisms enable on-demand delivery via environmental cues: pH-responsive silica, magnetic nanorod caps, smart hydrogels, glutathione-driven carriers, and light-activated nanoimpellers[5][6][12][15][17].
• Mechanistic understanding and modeling of release kinetics guides design and predictability, exemplified by kinetic modeling of PLGA microparticles and techno-formulations with defined release profiles[14][16][18].
• Surface engineering, mucoadhesion and targeting enhance residence time and site-specific delivery through functionalized nanoparticles and mucoadhesive systems for nasal or mucosal routes[9][11][19][20].
• Mainstreaming of drug-delivery systems as a pharmaceutical technology, evidenced by reviews and formulation strategies driving broader adoption and predictable development[2][14][18].

Influential works

• Hydrogels in drug delivery: Progress and challenges (2008)[4] surveys hydrogel chemistries, crosslinking, and stimuli-responsive strategies, outlining swelling-controlled release and biocompatibility that shaped later smart-release platforms and clinical progress.
• Hydrogels: from controlled release to pH-responsive drug delivery (2002)[14] traces gel-based release from diffusion-limited systems to pH-triggered designs, establishing fundamental principles for site-specific release and informing later responsive networks.
• Thermo- and pH-responsive polymers in drug delivery (2006)[12] reviews smart polymer systems capable of dual-trigger release, catalyzing the shift toward personalized dosing and triggering the growth of temperature/pH-responsive nanocarriers.
• Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers☆ (2008)[6] demonstrates tunable pore structure, high loading and protection of cargos, establishing a versatile nanocarrier platform that steered subsequent in vivo and gene therapy work.
• Nanosuspensions in drug delivery (2004)[7] introduces nanosized drug particles to boost solubility and bioavailability, detailing stabilization and scalable manufacturing, which spurred widespread adoption of nanoscale solid dispersions.

2010–2016

Stimuli-Responsive Gateable Delivery

Contemporary themes

During 2010–2016, controlled release research concentrated on programmable payload deployment via gateable nanostructures and stimuli-responsive carriers. Researchers engineered porous and multilayer platforms with gating strategies—nanovalves, disassembly-triggered release, and surface-functionalized coatings—to enable on-demand release in response to pH shifts, enzymatic cues, and redox conditions. Polymer-based carriers, including hydrogels and multilayer capsules, provided flexible platforms for localized delivery and tuning of release kinetics; mesoporous silica nanoparticles served as intracellular delivery hubs supporting autonomous, gated release. Remote actuation and theranostics emerged as key directions, combining magnetic or optical triggers with imaging to monitor and spatially control therapeutic outcomes.

• Stimuli-responsive release and gating across porous and multilayer carriers enabling on-demand drug release under pH, enzymatic, and redox cues via nanovalves, caps, and disassembly strategies.[6][7][11][16][12][8][14][18]
• Polymer-based carriers provide versatile platforms for controlled, localized delivery, combining pH-responsive polymers, hydrogels, and multilayer capsules to tune release and enable targeting.[5][10][15][9][6][2]
• Mesoporous silica nanoparticles serve as a dominant intracellular delivery platform using gated nanovalves, enzyme-triggered dissolution, and surface functionalization to achieve autonomous release.[14][16][12][11]
• Remote actuation and theranostics combine magnetic/DNA gates, remote triggering, and imaging to spatially control delivery and monitor outcomes.[3][4][19][9]

Influential works

The period solidified gateable and multi-stimuli responsive delivery as a central paradigm, establishing design principles for translating smart release concepts into clinically relevant platforms. Foundational work in biodegradable polymers such as poly(lactic-co-glycolic acid) and injectable chitosan hydrogels demonstrated robust, tunable degradation and depot formation, enabling sustained local therapy. The emergence of stimuli-responsive nanocarriers and dual/multi-stimuli systems provided scalable templates for site-specific release and set the stage for later integration with theranostic modalities and remote, image-guided control of therapy. In addition, cross-period inspirations—from light-responsive strategies leveraging atomically thin materials to advanced gating concepts—foreshadowed the convergence of hard and soft matter approaches in next-generation delivery systems.

• Atomically Thin MoS2: A New Direct-Gap Semiconductor introduced atomically thin MoS2 as a direct-gap semiconductor, unlocking light-responsive mechanisms for potential drug delivery platforms and laying groundwork for 2D-material–driven release strategies[3].
• Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier outlines PLGA's tunable biodegradability and release kinetics, establishing PLGA-based systems as the workhorse for sustained release and broad clinical translation[4].
• Chitosan-based hydrogels for controlled, localized drug delivery shows how injectable chitosan networks enable biocompatible, tunable crosslinking for local depots and sustained release, shaping subsequent hydrogel-based strategies[6].
• Stimuli-responsive nanocarriers for drug delivery synthesizes design strategies for pH, redox, temperature, and enzyme-triggered release, catalyzing the emergence of smart, triggerable systems and guiding later clinical and translational work[1].
• Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery demonstrates combining two or more triggers to achieve site-specific, programmable release, influencing multi-responsive designs and precision therapy approaches[13].

2017–2024

Stimuli-Responsive Drug Carriers

Contemporary themes

During 2017-2024, there is a clear convergence of stimuli-responsive platforms with practical delivery routes, including polymeric nanogels and hydrogels enabling on-demand payload release via pH, redox, thermo, or electric-field cues; microneedle-based systems advance painless transdermal and tissue delivery; and lipid-based carriers provide tunable release and site-specific delivery across diverse therapeutic modalities. The field increasingly emphasizes translation, closing the loop from design to market pathways and patient-centric delivery architectures.

• Stimuli-responsive polymeric nanogels and hydrogels enabling on-demand payload release via pH, redox, thermo, or electric-field cues, unifying responsive materials with controlled therapeutic delivery[1][13][14][17].
• Microneedle-based platforms empower painless, targeted transdermal and tissue delivery, combining dissolving microneedles, nanosuspension approaches and microfabrication to enhance permeability and patient compliance[2][8][10].
• Nanoparticle and lipid-based carriers—lipid nanocarriers, nanoemulsions, nanoprecipitation and related processing—enable site-specific delivery with tunable release kinetics across diverse therapeutic modalities[3][5][7][9][11].
• Hydrogel and biopolymer matrices deliver localized, sustained release through thermo-responsive and mucoadhesive systems, including thermo-sensitive hydrogels and chitosan-based gels[6][15][18].
• Strategic patterns spanning mechanism-to-translation organize controlled-release research: design strategies, process-to-market pathways, and industry uptake in drug-delivery technologies[9][12][17].

Influential works

These advances build on foundational nanoprecipitation methods that enabled scalable fabrication of polymeric nanoparticles with controlled size and loading; solid lipid nanoparticles and nanostructured lipid carriers offer stable, tunable lipid-based carriers with improved loading and biocompatibility relative to conventional liposomes; metal–organic frameworks provide stimuli-responsive options with high payloads and triggered release; engineering precision nanoparticles and microneedle platforms have shaped the agenda for targeted, controlled release and accelerated clinical translation and commercialization.

• Nanoprecipitation process: From encapsulation to drug delivery introduced solvent displacement to fabricate polymeric nanoparticles with controlled size, loading, and release. This scalable method enabled consistent, high-efficiency encapsulation, shaping modern controlled-release formulations and widespread adoption of polymeric carriers in drug delivery[7].
• Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems collectively document SLNs and NLCs as stable, tunable lipid-based carriers offering improved loading, controlled release, and biocompatibility relative to conventional liposomes, driving later clinical translations[10].
• Metal–Organic Framework‑Based Stimuli‑Responsive Systems for Drug Delivery surveys MOF materials capable of high payloads and triggered release under pH, redox, or light cues, highlighting design principles, biocompatibility considerations, and barriers; this work catalyzed rapid interest in MOF-based controlled-release platforms[12].
• Engineering precision nanoparticles for drug delivery discusses designing targeted, stimuli-responsive carriers with controlled release to reduce off-target effects, stressing manufacturability, reproducibility, and patient-specific payloads; it helped set the agenda for precision nanomedicine and regulatory planning[1].
• Microneedles: A smart approach and increasing potential for transdermal drug delivery system presents microneedle arrays as painless, localized delivery platforms enabling rapid, controlled release through the skin, with material choices and fabrication routes shaping clinical translation and commercialization[4].